News | April 05, 2021
Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The standout story remains Wegovy, particularly its new oral formulation
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Subscribe To Our Newsletter & Stay Updated
